Iterum Therapeutics PLC ITRMF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $1.6M
- P/E
- 0.0×
Follow ITRMF
Insider Buys
alert about insiders buying in the last 12 month
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
33.36 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(4.12) | — | — | — | |
P/B ratio |
0.00 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
57.72 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(2.72) | — | — | — | |
EV/FCF |
(2.72) | — | — | — | |
Quick Ratio |
1.78 | 2.35 | 3.49 | 1.37 | |
Current Ratio |
2.13 | 2.69 | 3.72 | 1.41 | |
Net Debt/EBITDA |
(1.38) | (1.47) | (2.54) | 1.35 | |
Debt/Assets |
65.27% | 60.72% | 62.79% | 45.52% | |
Debt/Equity |
(2.87) | (5.31) | (8.11) | (4.97) | |
Asset Turnover |
0.04 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 0.73 | 0.63 | 0.65 | |
Capex/Depreciation |
(0.03) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
323.33% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,664.36% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.58 | 0.56 | 0.59 | 0.44 | |
Share Based Compensation of Revenue |
13.59% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.85) | — | — | — | |
Graham Number |
1.65 | — | — | — | |
Earnings Yield |
(111.94%) | — | — | — | |
Free Cash Flow Yield |
(63.64%) | — | — | — | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.12) | (0.09) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.12) | (0.09) | (0.22) | |
Cash per Share |
0.24 | 0.33 | 0.37 | 1.22 | |
Shareholders Equity per Share |
(0.16) | (0.10) | (0.07) | (0.21) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.16) | (0.10) | (0.07) | (0.21) | |
Free Cash Flow |
(7.46) | (4.75) | (3.06) | (4.26) | |
Working Capital |
7.30 | 9.36 | 9.89 | 7.18 | |
Capital Expenditures |
(0.01) | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(26.16) | (23.01) | (22.02) | (23.89) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(2,302.31%) | 0.00% | 0.00% | 0.00% | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
0.24 | — | — | 0.11 | |
Average Payables |
0.71 | 1.01 | 1.69 | 2.62 | |
Average Assets |
24.21 | 24.09 | 26.30 | 35.43 | |
Average Common Equity |
(9.44) | (7.40) | (4.35) | (5.24) |
Columns are period end dates